Montpellier, France, May 18, 2015 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical robots, announced that it has received official authorization to market its ROSA™ robot in Australia for minimally invasive surgical procedures on the brain, and also spine surgery.
The Company also announced that it signed a distribution contract for Australia and New Zealand with Surgicom, a company specializing in the distribution and marketing of innovative medical devices, particularly in orthopedics. This agreement significantly reinforces Medtech’s geographical coverage in the Asia-Pacific region through Surgicom’s various offices and commercial agents in Sydney, Melbourne, Adelaide, Perth and Auckland. The entrance into the Australian and New Zealand markets further supports Medtech’s strategy to expand its international sales organization.
“This is an important milestone in the company’s development and ongoing expansion of our market opportunity. This authorization to market ROSA™ in Australia and the signing of a distribution agreement with Surgicom is a reflection of our strategy to increase our commercial presence at international level, including the Asia-Pacific region, where we already have strong momentum,” commented Bertin Nahum, President, CEO and Founder of Medtech.